annb0t
Top 20
Immutep Limited
New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patients Combination continues to be safe and well tolerated, and shows encouraging signs of antitumour activity in this difficult to treat patient population with limited treatment options Overall Response Rate (ORR) of 6% (2/36) and Disease Control Rate (DCR) of 36% (13/36) in the intent to treat populati...
>>> Read more: Immutep Announces Publication of TACTI-002 Abstract at ESMOâs European Lung Cancer Congress 2022
New interim data from TACTI-002 (Part B) evaluating the combination of efti and pembrolizumab in 2nd line, confirmed PD-1/PD-L1 refractory, non-small cell lung cancer (NSCLC) patients Combination continues to be safe and well tolerated, and shows encouraging signs of antitumour activity in this difficult to treat patient population with limited treatment options Overall Response Rate (ORR) of 6% (2/36) and Disease Control Rate (DCR) of 36% (13/36) in the intent to treat populati...
>>> Read more: Immutep Announces Publication of TACTI-002 Abstract at ESMOâs European Lung Cancer Congress 2022
